Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | BCL2A1 | Q16548 | 3/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | LSS | P48449 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.37 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6412640 | 0.77 | ALDH1A1 (0.68) | ALDH1A1HTTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL10157120 | 0.73 | ALDH1A1 (0.58) | ALDH1A1HTTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL11300231 | 0.72 | ALDH1A1 (0.66) | ALDH1A1HTTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL23641242 | 0.72 | ALDH1A1 (0.56) | ALDH1A1HTTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL9824160 | 0.71 | ALDH1A1 (0.70) | ALDH1A1HTTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL9824635 | 0.70 | ALDH1A1 (1.00) | ALDH1A1HTTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL13769106 | 0.70 | ALDH1A1 (0.58) | ALDH1A1HTTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL30131234 | 0.69 | ALDH1A1 (0.62) | ALDH1A1HTTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL11300012 | 0.69 | RAB9A (0.62) | ALDH1A1HTTRAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4415550 | 0.69 | RAB9A (0.66) | ALDH1A1HTTRAB9ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210276984-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | ASTEX THERAPEUTICS LIMITED (GB) | 2021-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210276984-A1 | ISOINDOLINONE INHIBITORS OF THE MDM2-P53 INTERACTION HAVING ANTICANCER ACTIVITY | TP53, MDM2, TP53BP1 | ALDH1A1 1400/4885HTT 352/4885RAB9A 3592/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.